We have shown that TTI‐CD200 treatment not only enhanced the function of autologous immune cells ex vivo but also significantly improved efficacy of adoptive immune effector CIK cells towards residual AML cells in vivo. The gene discussed is CD200; the disease is acute myeloid leukemia.